Oberlender R, Nichols D E
Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana.
J Pharmacol Exp Ther. 1990 Dec;255(3):1098-106.
The stimulus properties of 3,4-methylenedioxymethamphetamine (MDMA)-like compounds were studied in rats trained to discriminate saline from (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] hydrochloride (7.18 mumol/kg; 1.75 mg/kg), the alpha-ethyl homolog of MDMA. In previous experiments with (+)-MBDB as a test drug, complete substitution was observed for MDMA but not for (+)-lysergic acid diethylamide or (+)-amphetamine. In the study reported here, the (+)-MBDB cue generalized to MDMA and the parent drug, 3,4-methylenedioxyamphetamine. All three drugs exhibited a similar stereoselectivity, the (+)-isomer having potency greater than the (-)-isomer. By contrast, the hallucinogens, (+)-lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine and mescaline and the psychostimulants (+)-amphetamine and (+)-methamphetamine did not substitute for (+)-MBDB. Cocaine produced partial substitution. The results support the hypothesis that the primary behavioral activity of MDMA-like compounds is unlike that of hallucinogens and stimulants and may represent the effects of a novel drug class, given the name entactogens. Although the mechanism of action for the discriminative stimulus properties of MDMA-like compounds is not known, there is evidence that presynaptic serotonergic, but not dopaminergic, mechanisms are critical. Finally, 5,6-methylenedioxy-2-aminoindan a non-neurotoxic 3,4-methylenedioxyamphetamine rigid analog that was previously found to substitute for MDMA but not for (+)-lysergic acid diethylamide was found in the study described here to substitute completely for (+)-MBDB. The N-methyl derivative 5,6-methylenedioxy-2-methylminoindan produced similar results. The demonstration of entactogen-like discriminative stimulus properties, for drugs devoid of neuronal degenerative toxicity potential, serves as evidence of the independent mechanisms for these effects in rats.
在训练大鼠区分生理盐水与盐酸(+)-N-甲基-1-(1,3-苯并二氧杂环戊烯-5-基)-2-丁胺[(+)-MBDB](7.18微摩尔/千克;1.75毫克/千克)(MDMA的α-乙基同系物)的实验中,研究了3,4-亚甲基二氧甲基苯丙胺(MDMA)类化合物的刺激特性。在之前以(+)-MBDB作为测试药物的实验中,观察到MDMA可完全替代(+)-MBDB,但(+)-麦角酸二乙酰胺或(+)-苯丙胺则不能。在本文报道的研究中,(+)-MBDB线索可泛化至MDMA及其母体药物3,4-亚甲基二氧苯丙胺。这三种药物均表现出相似的立体选择性,(+)-异构体的效力大于(-)-异构体。相比之下,致幻剂(+)-麦角酸二乙酰胺、2,5-二甲氧基-4-甲基苯丙胺和三甲氧苯乙胺以及精神兴奋剂(+)-苯丙胺和(+)-甲基苯丙胺均不能替代(+)-MBDB。可卡因产生部分替代作用。这些结果支持了这样一种假说,即MDMA类化合物的主要行为活性不同于致幻剂和兴奋剂,鉴于其被命名为致幻剂,可能代表了一类新型药物的作用。尽管MDMA类化合物辨别刺激特性的作用机制尚不清楚,但有证据表明,突触前5-羟色胺能而非多巴胺能机制至关重要。最后,在本文所述研究中发现,5,6-亚甲基二氧-2-氨基茚满(一种非神经毒性的3,4-亚甲基二氧苯丙胺刚性类似物,此前发现可替代MDMA但不能替代(+)-麦角酸二乙酰胺)可完全替代(+)-MBDB。N-甲基衍生物5,6-亚甲基二氧-2-甲基氨基茚满产生了类似结果。对于缺乏神经元退行性毒性潜力的药物,致幻剂样辨别刺激特性的证明,为大鼠中这些效应的独立机制提供了证据。